BACKGROUND: Bone marrow transplantation (BMT) is an established therapy for a variety of hematological diseases with curative potential. However, despite improvements in supportive care, pulmonary complications remain a significant cause of morbidity and mortality. METHODS: We report on a patient who received a double lung transplantation (LTX) for therapy-refractory bronchiolitis obliterans (BO) associated with extensive chronic graft-versus-host disease (GVHD) after allogeneic BMT. RESULTS: At present, 38 months after BMT and 23 months after LTX, the patient is in complete hematological and cytogenetic remission and without signs of respiratory distress. CONCLUSIONS: This case illustrates that lung transplantation could be a therapeutic option in selected patients with BO after allogeneic BMT that is associated with extensive chronic GVHD and who are refractory to conventional immunosuppressive therapy.
BACKGROUND: Bone marrow transplantation (BMT) is an established therapy for a variety of hematological diseases with curative potential. However, despite improvements in supportive care, pulmonary complications remain a significant cause of morbidity and mortality. METHODS: We report on a patient who received a double lung transplantation (LTX) for therapy-refractory bronchiolitis obliterans (BO) associated with extensive chronic graft-versus-host disease (GVHD) after allogeneic BMT. RESULTS: At present, 38 months after BMT and 23 months after LTX, the patient is in complete hematological and cytogenetic remission and without signs of respiratory distress. CONCLUSIONS: This case illustrates that lung transplantation could be a therapeutic option in selected patients with BO after allogeneic BMT that is associated with extensive chronic GVHD and who are refractory to conventional immunosuppressive therapy.
Authors: Jason A Dubovsky; Ryan Flynn; Jing Du; Bonnie K Harrington; Yiming Zhong; Benjamin Kaffenberger; Carrie Yang; William H Towns; Amy Lehman; Amy J Johnson; Natarajan Muthusamy; Steven M Devine; Samantha Jaglowski; Jonathan S Serody; William J Murphy; David H Munn; Leo Luznik; Geoffrey R Hill; Henry K Wong; Kelli K P MacDonald; Ivan Maillard; John Koreth; Laurence Elias; Corey Cutler; Robert J Soiffer; Joseph H Antin; Jerome Ritz; Angela Panoskaltsis-Mortari; John C Byrd; Bruce R Blazar Journal: J Clin Invest Date: 2014-10-01 Impact factor: 14.808
Authors: G C Hildebrandt; T Fazekas; A Lawitschka; H Bertz; H Greinix; J Halter; S Z Pavletic; E Holler; D Wolff Journal: Bone Marrow Transplant Date: 2011-03-28 Impact factor: 5.483